Promises, promises, and precision medicine

Epidemiology in wonderland: Big Data and precision medicine

(2018) Rodolfo Saracci   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials

(2018) Vanessa Selak et al.   HEART

Estimation of The Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology

(2018) John Marquart et al.   JAMA Oncology

Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States

(2018) Dolly Sharma et al.   Orphanet Journal of Rare Diseases

Functional precision cancer medicine—moving beyond pure genomics

(2017) Anthony Letai   NATURE MEDICINE

Marginal role for 53 common genetic variants in cardiovascular disease prediction

(2016) Richard W Morris et al.   HEART

Value of Personalized Medicine

(2016) Ralph Snyderman et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis

(2016) Jack W. Scannell et al.   PLoS One

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

(2015) Christophe Le Tourneau et al.   LANCET ONCOLOGY

PCSK9: From discovery to therapeutic applications

(2014) Michel Farnier   Archives of Cardiovascular Diseases

Genotype-Guided vs Clinical Dosing of Warfarin and Its Analogues

(2014) Kathleen Stergiopoulos et al.   JAMA Internal Medicine

Cigarette smoking and lung cancer-relative risk estimates for the major histological types from a pooled analysis of case-control studies

(2011) Beate Pesch et al.   INTERNATIONAL JOURNAL OF CANCER